New insider activity at Syndax Pharmaceuticals ( (SNDX) ) has taken place on February 13, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Syndax Pharmaceuticals, CFO and SVP Keith Goldan sold 3,777 shares, totaling $58,543. Meanwhile, Director Michael Metzger offloaded 13,288 shares, garnering $205,964. Additionally, President and Head of R&D Gallagher Neil sold 4,618 shares for $71,579.
More about Syndax Pharmaceuticals
YTD Price Performance: 6.61%
Average Trading Volume: 2,482,252
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.29B